INTERVIEW TO PROF. MASSIMO DI MAIO

Health-related quality of life (QoL) is universally considered a measure of clinical benefit for patients with cancer, but its inclusion in clinical trials has historically been suboptimal. The recognition of the role of QoL and patient-reported outcomes in the evaluation of new agents by regulatory agencies and in the definition of treatment value is constantly increasing. ARO editors asked Prof. Massimo Di Maio, from the Department of Oncology, University of Turin and National Secretary of the Italian Association of Medical Oncology, critical questions about the use of patient-reported outcomes in clinical trials conducted in Oncology.